⚕ GalenOps field
←

SITE014-0385

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2023-05-25

AEs
8
Serious
0
Dropout signal
–

Adverse events

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-06-17 (study day 4); relationship: not assessed

mild assessed

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-07-10 (study day 27); relationship: N

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-07-16 (study day 33); relationship: N

mild assessed

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-07-18 (study day 35); relationship: not assessed

moderate assessed

Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-09-26 (study day 105); relationship: not assessed

mild assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-10-04 (study day 113); relationship: not assessed

moderate assessed

Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-12-31 (study day 201); relationship: not assessed

severe assessed

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-01-11 (study day 212); relationship: N

Data queries

No data queries.